Nulibry
What Nulibry is used for
Nulibry is indicated for the treatment of patients with molybdenum cofactor deficiency (MoCD) Type A.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Nulibry
- Active substance
- fosdenopterin
- Disease area
- Metal Metabolism, Inborn Errors
- Medicine group
- Other alimentary tract and metabolism products
- ATC code
- A16AX19
- Marketing authorisation holder
- Integral Pharma Solutions EU Limited
- Authorised in the EU since
- 2022
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Nulibry used for?
Nulibry is indicated for the treatment of patients with molybdenum cofactor deficiency (MoCD) Type A.
What is the active substance in Nulibry?
Nulibry contains fosdenopterin.
Who makes Nulibry?
The EU marketing authorisation holder is Integral Pharma Solutions EU Limited.
Is Nulibry an orphan medicine?
Yes. Nulibry is designated an orphan medicine in the EU, for a rare disease (Metal Metabolism, Inborn Errors).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU